Insulet
NASDAQ: PODDActon, US · 5,430 employees on LinkedIn · 2 known investors
Insulet is the maker of Omnipod, a line of tubeless, wearable, waterproof Pod-based insulin management systems that deliver continuous insulin without multiple daily injections. The company builds medical devices for people living with diabetes and operates in 26 countries.
Investors · 2
Competitors · 2
by search overlap
DexCom90 shared keywordsDexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
Diabetes63 shared keywordsThe American Diabetes Association is a nonprofit organization focused on diabetes prevention, research, advocacy, and education, providing resources, community programs, and support for people living with diabetes and prediabetes in the United States. It also advocates for policy such as affordable insulin and hosts scientific and technology conferences.
Companies competing with Insulet for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Insulet (PODD) Stock Slumps As Earnings Beat Collides With Guidance Reset - StocksToTradestockstotrade.com · Aug 2026Frequently asked questions
- What does Insulet do?
- Insulet is the maker of Omnipod, a line of tubeless, wearable, waterproof Pod-based insulin management systems that deliver continuous insulin without multiple daily injections. The company builds medical devices for people living with diabetes and operates in 26 countries.
- Who are Insulet's investors?
- Insulet's investors include SV Health Investors, Winklevoss Capital.
- Where is Insulet headquartered?
- Insulet is headquartered in Acton, US.